(AKRO) Akero Therapeutics - Ratings and Ratios
Efruxifermin, EFX, MASH Treatment
AKRO EPS (Earnings per Share)
AKRO Revenue
Description: AKRO Akero Therapeutics
Akero Therapeutics Inc (NASDAQ:AKRO) is a biotechnology company focused on developing treatments for serious metabolic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH). Their lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 that regulates metabolism and protects against cellular stress.
From a financial perspective, Akero Therapeutics has a market capitalization of $4.15 billion, indicating a significant presence in the biotechnology sector. The absence of a price-to-earnings (P/E) ratio suggests that the company is not yet profitable, which is common for companies in the development stage. The return on equity (RoE) of -31.98% indicates that the company is currently generating losses, likely due to research and development expenses.
To evaluate the companys potential, we can consider key performance indicators (KPIs) such as the progress of their clinical trials, the competitive landscape of the MASH treatment market, and the companys cash burn rate. A crucial KPI for Akero Therapeutics is the advancement of efruxifermin through clinical trials, particularly the Phase III trials, as positive results could lead to FDA approval and significantly impact the stock price.
Additionally, the partnership with Amgen Inc. is a significant factor in Akero Therapeutics potential success, as it provides validation of their technology and could lead to future milestones and royalties. Monitoring the companys cash reserves and burn rate will be essential to understanding their ability to continue funding their research and development efforts without needing additional capital.
Overall, Akero Therapeutics success will depend on the efficacy and safety of efruxifermin, as well as their ability to navigate the complex landscape of regulatory approvals and market competition. As a Trading Analyst, it is essential to closely monitor the companys clinical trial results, financial health, and partnerships to make informed investment decisions.
AKRO Stock Overview
| Market Cap in USD | 3,522m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2019-06-20 |
AKRO Stock Ratings
| Growth Rating | 60.0% |
| Fundamental | 22.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 33.6% |
| Analyst Rating | 4.75 of 5 |
AKRO Dividends
Currently no dividends paidAKRO Growth Ratios
| Growth Correlation 3m | -91.9% |
| Growth Correlation 12m | 70.6% |
| Growth Correlation 5y | 34.8% |
| CAGR 5y | 17.02% |
| CAGR/Max DD 3y | 0.21 |
| CAGR/Mean DD 3y | 0.64 |
| Sharpe Ratio 12m | -0.43 |
| Alpha | 0.00 |
| Beta | 0.000 |
| Volatility | 63.90% |
| Current Volume | 1156.1k |
| Average Volume 20d | 808.2k |
| Stop Loss | 39.9 (-5.4%) |
| Signal | -0.70 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-284.0m TTM) > 0 and > 6% of Revenue (6% = 240.0 TTM) |
| FCFTA -0.21 (>2.0%) and ΔFCFTA -3.94pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 17.6m% (prev 262.3k%; Δ 17.3mpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.23 (>3.0%) and CFO -253.4m > Net Income -284.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 12.66 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (81.7m) change vs 12m ago 18.16% (target <= -2.0% for YES) |
| Gross Margin 25.0% (prev 96.83%; Δ -71.83pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.00% (prev 0.03%; Δ -0.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -43.98 (EBITDA TTM -209.8m / Interest Expense TTM 4.77m) >= 6 (WARN >= 3) |
Altman Z'' -12.28
| (A) 0.63 = (Total Current Assets 764.6m - Total Current Liabilities 60.4m) / Total Assets 1.11b |
| (B) -0.87 = Retained Earnings (Balance) -967.4m / Total Assets 1.11b |
| (C) -0.21 = EBIT TTM -209.9m / Avg Total Assets 987.1m |
| (D) -11.60 = Book Value of Equity -966.4m / Total Liabilities 83.3m |
| Total Rating: -12.28 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 22.67
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -8.17% = -4.09 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.04 = 2.50 |
| 5. Debt/Ebitda -0.18 = -2.50 |
| 6. ROIC - WACC (= -28.43)% = -12.50 |
| 7. RoE -31.57% = -2.50 |
| 8. Rev. Trend -3.94% = -0.30 |
| 9. EPS Trend -59.00% = -2.95 |
What is the price of AKRO shares?
Over the past week, the price has changed by -2.47%, over one month by -13.19%, over three months by -23.86% and over the past year by +58.33%.
Is Akero Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AKRO is around 40.17 USD . This means that AKRO is currently overvalued and has a potential downside of -4.77%.
Is AKRO a buy, sell or hold?
- Strong Buy: 9
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AKRO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 77.4 | 83.4% |
| Analysts Target Price | 77.4 | 83.4% |
| ValueRay Target Price | 43.8 | 3.8% |
Last update: 2025-09-06 04:30
AKRO Fundamental Data Overview
CCE Cash And Equivalents = 742.3m USD (Cash And Short Term Investments, last quarter)
P/B = 3.5573
Beta = -0.243
Revenue TTM = 4000 USD
EBIT TTM = -209.9m USD
EBITDA TTM = -209.8m USD
Long Term Debt = 22.2m USD (from longTermDebt, last quarter)
Short Term Debt = 14.7m USD (from shortTermDebt, last quarter)
Debt = 36.8m USD (Calculated: Short Term 14.7m + Long Term 22.2m)
Net Debt = -206.6m USD (from netDebt column, last quarter)
Enterprise Value = 2.82b USD (3.52b + Debt 36.8m - CCE 742.3m)
Interest Coverage Ratio = -43.98 (Ebit TTM -209.9m / Interest Expense TTM 4.77m)
FCF Yield = -8.17% (FCF TTM -230.1m / Enterprise Value 2.82b)
FCF Margin = -5.75m% (FCF TTM -230.1m / Revenue TTM 4000 )
Net Margin = -7.10m% (Net Income TTM -284.0m / Revenue TTM 4000 )
Gross Margin = 25.0% ((Revenue TTM 4000 - Cost of Revenue TTM 3000 ) / Revenue TTM)
Tobins Q-Ratio = -2.91 (set to none) (Enterprise Value 2.82b / Book Value Of Equity -966.4m)
Interest Expense / Debt = 3.18% (Interest Expense 1.17m / Debt 36.8m)
Taxrate = 21.0% (US default)
NOPAT = -209.9m (EBIT -209.9m, no tax applied on loss)
Current Ratio = 12.66 (Total Current Assets 764.6m / Total Current Liabilities 60.4m)
Debt / Equity = 0.04 (Debt 36.8m / last Quarter total Stockholder Equity 1.03b)
Debt / EBITDA = -0.18 (Net Debt -206.6m / EBITDA -209.8m)
Debt / FCF = -0.16 (Debt 36.8m / FCF TTM -230.1m)
Total Stockholder Equity = 899.5m (last 4 quarters mean)
RoA = -25.60% (Net Income -284.0m, Total Assets 1.11b )
RoE = -31.57% (Net Income TTM -284.0m / Total Stockholder Equity 899.5m)
RoCE = -22.77% (Ebit -209.9m / (Equity 899.5m + L.T.Debt 22.2m))
RoIC = -22.45% (NOPAT -209.9m / Invested Capital 934.9m)
WACC = 5.98% (E(3.52b)/V(3.56b) * Re(6.02%)) + (D(36.8m)/V(3.56b) * Rd(3.18%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 7.04%
Discount Rate = 6.02% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -230.1m)
EPS Correlation: -59.00 | EPS CAGR: 9.24% | SUE: 0.38 | # QB: 0
Revenue Correlation: -3.94 | Revenue CAGR: 0.0% | SUE: N/A | # QB: None
Additional Sources for AKRO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle